This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
MARIETTA, Ga., July 2, 2013 /PRNewswire/ --
MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has been included in the Russell 2000®, the Russell 3000 and the Russell Global Indexes effective at the start of trading on
July 1, 2013.
Membership in the Russell indexes, which remains in place for one year, means automatic inclusion in the appropriate market capitalization weighted indexes as well as the appropriate growth and value style indexes. Russell determines membership for its equity indexes primarily by objective, market-capitalization rankings and style attributes.
The Russell 2000 Index measures the performance of the small-cap segment of the U.S. equity universe. It is a subset of the Russell 3000
Index and it represents approximately 8% of the U.S. market. "We are extremely pleased to have MiMedx's common stock selected for this prestigious index. We are pleased with our Company's performance, and we view this selection into the Russell 2000 as affirmation of the future outlook for our company," said Parker H. "Pete" Petit, MiMedx Chairman and CEO.
Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for both passive and active investment strategies. Approximately
$4.1 trillion in assets currently are benchmarked to these indexes. Russell calculates more than 700,000 benchmarks daily covering approximately 98% of the investable market globally, 80 countries and more than 10,000 securities.
The Russell 2000 Index includes approximately 2,000 of the smallest securities based on a combination of their market cap and current index membership. The Russell 2000 Index is constructed to provide a comprehensive and unbiased barometer for the small-cap segment and is completely reconstituted annually to ensure larger stocks do not distort the performance and characteristics of the true small-cap opportunity set.